2024-2025 COVID-19 vaccines reduced hospitalization risk by 40% against JN.1 lineage variants. COVID-19 is still a public threat and health concern. Between 2024 and 2025, an estimated 380,000 to ...

Data in this new study shows that the 2024–2025 COVID-19 vaccines provide similar protection to the previous formulation. They were found to be most protective four weeks after vaccination, providing ...

Latest news and updates on the impact of a new strain of coronavirus on mainland China. The first cases of the virus, which ...

Changes in the vaccine advisory process in the United States have disrupted immunization guidance, which reinforces the need for independent evidence review to inform decisions regarding immunization ...

Three COVID vaccines are available for children in different age groups: Moderna (6 months or older with at least one qualifying health condition), Pfizer (5 years or older), and Novavax (12 years or ...

Pfizer Chairman and CEO Albert Bourla speaks (C) as (L-R) Director of Medicare and Deputy Administrator of CMS Chris Klomp, U.S. Secretary of Health and Human Services Robert F. Kennedy Jr., ...

Stone is a retired infectious disease physician, medical journalist, and author. Feinberg is professor of medicine/infectious disease and professor of behavioral medicine and psychiatry at the West ...